# CoraLite® Plus 750 Anti-Human CD29 (TS2/16) 

Catalog Number:CL750-65191

| Basic Information | Catalog Number: CL750-65191 | GenBank Accession Number: BC020057 | Purification Method: Affinity purification |
| :---: | :---: | :---: | :---: |
|  | Size: <br> 100tests, $5 \mu \mathrm{l}$ /test | $\begin{aligned} & \text { GenelD (NCBI): } \\ & 3688 \end{aligned}$ | $\begin{aligned} & \text { CloneNo.: } \\ & \text { TS2/16 } \end{aligned}$ |
|  | Source: <br> Mouse | ENSEMBL Gene ID: <br> ENSG00000150093 | Excitation/Emission maxima wavelengths: |
|  | Isotype: lgG1, kappa | UNIPROT ID: P05556 | $755 \mathrm{~nm} / 780 \mathrm{~nm}$ |
|  |  | Full Name: integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF 2, MSK12) |  |
|  |  | Calculated MW: $88 \text { kDa }$ |  |

Applications
Tested Applications:
FC
Species Specificity:
Human

Background Information
Integrin beta-1 (ITGB1), also named as CD29, is a 130 kDa single chain type I glycoprotein that is expressed in a heterodimeric complex with one of six distinct a subunits, comprising the very late activation antigen (VLA) subfamily of adhesion receptors. It is one of the essential surface molecules expressed on human MSC from bone marrow and other sources. The $\beta 1$ subunit is also broadly expressed on lymphocytes and monocytes, weakly expressed on granulocytes, and not expressed on erythrocytes. These receptors are involved in a variety of cell-cell and cell-matrix interactions.

Storage

Storage:
Store at $2-8^{\circ} \mathrm{C}$. Avoid exposure to light. Stable for one year after shipment.
Storage Buffer:
PBS with $0.09 \%$ sodium azide and $0.5 \%$ BSA.

$1 \times 10^{\wedge} 6$ human PBMCs were surface stained with 5 ul CoraLite® Plus 750 Anti-Human CD29 (CL75065191, Clone:TS2/16) or unstained. Cells were not fixed. Monocytes were gated.

1 $\times 10^{\wedge} 6$ human PBMCs were surface stained with 5
ul CoraLite® Plus 750 Anti-Human CD29 (CL750-
65191, Clone:TS2/16) or unstained. Cells were not fixed. Monocytes were gated.

